Filtered By:
Condition: Disability
Drug: Aspirin

This page shows you your search results in order of date.

Order by Relevance | Date

Total 65 results found since Jan 2013.

Dual Versus Mono Antiplatelet Therapy in Patients with Acute Mild-to-Moderate Stroke: A Multicentre Perspective Cohort Study
ConclusionAspirin plus clopidogrel was associated with a reduction in the incidence of disability attributed to index stroke. There was no statistically significant difference in the incidence of moderate to severe bleeding complications between the two antiplatelet drug regimens.Trial Registration NumberChiCTR1900025214.
Source: Cardiovascular Drugs and Therapy - June 13, 2023 Category: Cardiology Source Type: research

Contemporary Antiplatelet and Anticoagulant Therapies for Secondary Stroke Prevention: A Narrative Review of Current Literature and Guidelines
AbstractPurpose of ReviewStroke is a leading cause of death and disability worldwide. The annual incidence of new or recurrent stroke is approximately 795,000 cases per year in the United States, of which 87% are ischemic in nature. In addition to the management of modifiable high-risk factors to reduce the risk of recurrent stroke, antithrombotic agents (antiplatelets and anticoagulants) play an important role in secondary stroke prevention. This review will discuss the published literature on the use of antiplatelets and anticoagulants in secondary prevention of acute ischemic stroke and transient ischemic attack (TIA), ...
Source: Current Neurology and Neuroscience Reports - April 11, 2023 Category: Neuroscience Source Type: research

New VOYAGER PAD Analysis Confirms Consistent Benefit of XARELTO ® (rivaroxaban) Plus Aspirin Following Lower Extremity Revascularization (LER)
TITUSVILLE, NJ, March 5, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from a new prespecified analysis from the Phase 3 VOYAGER PAD clinical trial reinforcing the benefits of the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily plus aspirin 100 mg once daily) over standard of care (aspirin alone), demonstrating consistent benefit at 30 days, 90 days and up to three years following LER in patients with PAD. Lower extremity revascularization, also called peripheral revascularization, is a procedure that restores blood flow in blocked arteries or veins. This analysis of ...
Source: Johnson and Johnson - March 5, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news

Early identification and treatment for peripheral arterial disease in patients with ischemic cerebrovascular disease
Eur J Med Res. 2023 Feb 23;28(1):93. doi: 10.1186/s40001-023-01050-5.ABSTRACTIschemic cerebrovascular disease (ICVD) is a major cause of mortality and disability worldwide and is often caused by atherosclerosis. As a systemic disease, atherosclerosis usually affects multiple vascular beds, mainly including cerebral, coronary, and peripheral arteries. Therefore, ICVD is easily complicated by lower-extremity peripheral arterial disease (PAD). ICVD patients with PAD have more serious symptoms and a worse prognosis, however, neurologists might neglect the evaluation and management of the coexistent PAD, and there is still a la...
Source: Atherosclerosis - February 24, 2023 Category: Cardiology Authors: Lu-Guang Li Xin Ma Source Type: research

Factors affecting self-reported bleeding acceptance in acute ischemic stroke survivors on various types of antithrombotic therapy
Stroke causes long-term serious disability with global prevalence of 101 million people in 2019.1 Antithrombotic therapy is recommended for stroke secondary prevention depending on the acute ischemic stroke (AIS) subtype.2 One of the major causes of non-cardioembolic AIS is intracranial atherosclerosis, which requires single antiplatelet therapy (SAPT), mostly with aspirin.3,4 Dual antiplatelet therapy (DAPT) may reduce the risk of non-cardioembolic stroke by 29% in AIS attributable to severe intracranial stenosis when used for a limited period of time.
Source: Journal of Stroke and Cerebrovascular Diseases - November 16, 2022 Category: Neurology Authors: Gabriela Rusin, Jadwiga Kubica, Krzysztof Piotr Malinowski, Agnieszka S łowik, Anetta Undas Source Type: research

Antithrombotic therapy for secondary prevention in patients with stroke or transient ischemic attack: A multiple treatment network meta-analysis of randomized controlled trials
ConclusionThe prognosis of patients with an ischemic stroke or transient ischemic attack is improved with antiplatelets. Cilostazol showed the best risk-benefit characteristics without trade-off with the risk of major bleeding. Improved stroke recurrence with intensified antiplatelet regimens is counterbalanced with higher bleeding risk, and consequently, mortality remains unaffected. Treatment decisions in stroke survivals should integrate the assessment of bleeding risk for better identification of patients with the highest benefit of treatment intensification. Systematic review registrationProspero registration number: ...
Source: PLoS One - August 17, 2022 Category: Biomedical Science Authors: D ániel Tornyos Source Type: research

E-176 Endovascular stent retriever thrombectomy of medium and small vessel occlusion of the middle cerebral artery with acute ischemic stroke: a case series
ConclusionsOur case series demonstrated that SRMT in SVO with disabling NIHSS is feasible and safe if performed carefully. All patient achieved TICI 3 perfusion and first pass effect was better observed in trap technique and use of long solitaire STD. Good function outcomes were achieved in all cases irrespective of the types of SRD used and passes required to achieve TICI 3 perfusion. Further studies are required.Disclosures Y. Lodi: None.
Source: Journal of NeuroInterventional Surgery - July 23, 2022 Category: Neurosurgery Authors: Lodi, Y. Tags: SNIS 19th annual meeting electronic poster abstracts Source Type: research

A Review of the Role of Transthoracic and Transesophageal Echocardiography, Computed Tomography, and Magnetic Resonance Imaging in Cardioembolic Stroke
Med Sci Monit. 2022 Jun 22;28:e936365. doi: 10.12659/MSM.936365.ABSTRACTStroke is a major source of morbidity and mortality worldwide, accounting for the second largest cause of mortality and the third greatest cause of disability. Stroke is frequently preceded by a transient ischemic attack (TIA). The etiologies of 20-30% of ischemic strokes are unknown, and thus are termed "cryptogenic strokes". About 25% of ischemic strokes are cardioembolic. Strokes occur at a rate of around 2% per year in individuals with heart failure with reduced ejection fraction (HFrEF), with a strong correlation between stroke risk and the degree...
Source: Medical Science Monitor - June 22, 2022 Category: Research Authors: Sergiu Florin Arnautu Diana Aurora Arnautu Ana Lascu Andrei A Hajevschi Ciprian Ilie Ilie Rosca Abhinav Sharma Dragos Catalin Jianu Source Type: research

Efficacy and safety of clopidogrel and/or aspirin for ischemic stroke/transient ischemic attack: An overview of systematic reviews and meta-analysis
Conclusions: High-quality evidence suggested that clopidogrel plus aspirin was more efficient than monotherapy, although the risk for hemorrhagic stroke was relatively higher in combined therapy regimens lasting>1 month.
Source: Medicine - December 17, 2021 Category: Internal Medicine Tags: Research Article: Systematic Review and Meta-Analysis Source Type: research

Reduction in Acute Limb Ischemia with Rivaroxaban versus Placebo in Peripheral Artery Disease after Lower Extremity Revascularization: Insights from VOYAGER PAD
Conclusions: After LER for symptomatic PAD, ALI is frequent, particularly early after LER, and is associated with poor prognosis. Low-dose rivaroxaban plus aspirin reduces ALI after LER, including ALI events associated with the most severe outcomes. The benefit of rivaroxaban for ALI appears early, continues over time, and is consistent regardless of revascularization approach or clopidogrel use.PMID:34637332 | DOI:10.1161/CIRCULATIONAHA.121.055146
Source: Circulation - October 12, 2021 Category: Cardiology Authors: Connie N Hess E Sebastian Debus Mark R Nehler Sonia S Anand Manesh R Patel Michael Szarek Warren H Capell Judith Hsia Joshua A Beckman Marianne Brodmann Rafael Diaz Peter Habertheuer Nicholas J Leeper Richard J Powell Henrik Sillesen Eva Muehlhofer Scott Source Type: research

Human placenta mesenchymal stem cell protection in ischemic stroke is angiotensin converting enzyme ‐2 and masR receptor‐dependent
Angiotensin converting enzyme-2 (ACE-2) contributes to human placenta mesenchymal stem cell (hPMSC)-induced protection against ischemic injury through MasR pathway. AbstractThromboembolic stroke remains a major cause of neurological disability and death. Current stroke treatments (aspirin, tissue plasminogen activator) are significantly limited by timing and risks for hemorrhage which have driven researchers to explore other approaches. Stem cell-based therapy appears to be an effective option for ischemic stroke. Besides trans-differentiation into neural cells, stem cells also provide acute protection via paracrine signal...
Source: Stem Cells - June 22, 2021 Category: Stem Cells Authors: Mansoureh Barzegar, Shantel Vital, Karen Y. Stokes, Yuping Wang, Jungmi Winny Yun, Luke A. White, Oleg Chernyshev, Roger E. Kelley, Jonathan S. Alexander Tags: Regenerative Medicine Source Type: research

Human placenta mesenchymal stem cell protection in ischemic stroke is Angiotensin converting enzyme ‐2 (ACE‐2) and masR receptor dependent
In this study we demonstrated that hPMSC-derived ACE2 is required to protect against progressive loss of cerebral blood perfusion following ischemic stroke. This effect is also mediated through vascular endothelial Mas receptor but not AT2 receptor. Consequently, the results of our experimental stroke studies with human derived stem cells describes new paracrine function of hPMSC in which ACE2 and Mas receptor are critical, therefore, providing a novel therapeutic strategy for stroke in near future.
Source: Stem Cells - June 15, 2021 Category: Stem Cells Authors: Mansoureh Barzegar, Shantel Vital, Karen Y. Stokes, Yuping Wang, J. Winny Yun, Luke A. White, Oleg Chernyshev, Roger E. Kelley, Jonathan S. Alexander Tags: Regenerative Medicine Source Type: research